14 research outputs found
One-Pot Synthesis of Deuterated Aldehydes from Arylmethyl Halides
A facile, one-pot
approach for synthesizing deuterated aldehydes
from arylmethyl halides was developed using D<sub>2</sub>O as the
deuterium source. The efficient process is realized by a sequence
of formation, H/D exchange, and oxidation of pyridinium salt intermediates.
The mild and air-compatible reaction conditions enable efficient synthesis
of diverse deuterated aldehydes with high deuterium incorporation
Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors
An
organocatalytic enantioselective Michael–Michael cascade
reaction is developed for the synthesis of chiral spirotetrahydrothiopyrans.
This highly functionalized scaffold was assembled in moderate to good
yield (55–74%) and excellent diastereo- and enantioselectivities
(>30:1 dr, ≥ 99% ee) with the creation of four consecutive
stereogenic centers. The novel spiro-oxindole scaffold is validated
as a new class of p53-MDM2 protein–protein interaction inhibitors
with good antitumor activity
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
p53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound <b>14d</b> was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound <b>14d</b> showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
p53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound <b>14d</b> was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound <b>14d</b> showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
p53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound <b>14d</b> was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound <b>14d</b> showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
p53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound <b>14d</b> was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound <b>14d</b> showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
p53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound <b>14d</b> was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound <b>14d</b> showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
In order to take
advantage of both immunotherapeutic and epigenetic
antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase
1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.
The highly active dual inhibitor <b>10</b> showed excellent
and balanced activity against both IDO1 (IC<sub>50</sub> = 69.0 nM)
and HDAC1 (IC<sub>50</sub> = 66.5 nM), whose dual targeting mechanisms
were validated in cancer cells. Compound <b>10</b> had good
pharmacokinetic profiles as an orally active antitumor agent and significantly
reduced the l-kynurenine level in plasma. In particular,
it showed excellent <i>in vivo</i> antitumor efficacy in
the murine LLC tumor model with low toxicity. This proof-of-concept
study provided a novel strategy for cancer treatment. Compound <b>10</b> represents a promising lead compound for the development
of novel antitumor agents and can also be used as a valuable probe
to clarify the relationships and mechanisms between cancer immunotherapy
and epigenetics
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
p53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound <b>14d</b> was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound <b>14d</b> showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery
Facile Construction of Structurally Diverse Thiazolidinedione-Derived Compounds via Divergent Stereoselective Cascade Organocatalysis and Their Biological Exploratory Studies
In
this article, we present a new approach by merging two powerful
synthetic tactics, divergent synthesis and cascade organocatalysis,
to create a divergent cascade organocatalysis strategy for the facile
construction of new “privileged” substructure-based
DOS (pDOS) library. As demonstrated, notably 5 distinct molecular
architectures are produced facilely from readily available simple
synthons thiazolidinedione and its analogues and α,β-unsaturated
aldehydes in 1–3 steps with the powerful strategy. The beauty
of the chemistry is highlighted by the efficient formation of structurally
new and diverse products from structurally close reactants under the
similar reaction conditions. Notably, structurally diverse spiro-thiazolidinediones
and -rhodanines are produced from organocatalytic enantioselective
3-component Michael–Michael–aldol cascade reactions
of respective thiazolidinediones and rhodanines with enals. Nevertheless,
under the similar reaction conditions, reactions of isorhodanine via
a Michael–cyclization cascade lead to structurally different
fused thiopyranoid scaffolds. This strategy significantly minimizes
time- and cost-consuming synthetic works. Furthermore, these molecules
possess high structural complexity and functional, stereochemical,
and skeletal diversity with similarity to natural scaffolds. In the
preliminary biological studies of these molecules, compounds <b>4f</b>, <b>8a</b>, and <b>10a</b> exhibit inhibitory
activity against the human breast cancer cells, while compounds <b>8a</b>, <b>9a</b>, and <b>9b</b> display good antifungal
activities against <i>Candida albicans</i> and <i>Cryptococcus
neoformans</i>. Notably, their structures are different from
clinically used triazole antifungal drugs. Therefore, they could serve
as good lead compounds for the development of new generation of antifungal
agents